NRFC backs mind-controlled tech as Synchron raises $308m
Melbourne-based neurotechnology company Synchron has secured US$200 million (AUD$308 million) in its Series D funding round. Of this, AU$54 million was contributed by Australia’s National Reconstruction Fund Corporation (NRFC).
Innovative Brain-Computer Interface
Founded in 2016 by Nicholas Opie, Tom Oxley, and Rahul Sharma, Synchron is developing a brain-computer interface (BCI) known as Stentrode. This device allows individuals to control external digital devices using their thoughts without requiring open-brain surgery.
How the Stentrode Works
The Stentrode implant is introduced through the jugular vein via a small incision in the neck. It is then guided into a large blood vessel near the brain’s motor cortex, the region responsible for planning and controlling body movements.
Once implanted, the device detects neural activity related to the user’s intentions. These signals are transmitted to an antenna placed beneath the chest skin, which wirelessly connects to external devices like computers and smartphones.
Future Development and Goals
The new funding will support ongoing clinical trials, preparation for the commercial rollout of the Stentrode system, and team expansion including engineers and neuroscientists.
“We’ve built the first non-surgical brain-computer interface designed for everyday life for people with paralysis,” said founder and CEO Tom Oxley.
Author’s Summary
Synchron’s groundbreaking brain implant secured $308 million to advance trials and bring non-surgical mind-control technology closer to real-world use.